Ruslan D. Novosiadly

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David Schaer, Richard P. Beckmann, Jack Dempsey et al. · Cell Reports · 2018 · 460 citations · Full text

Medicine, Immunology, Pharmacology +17

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Rikke Holmgaard, David Schaer, Yanxia Li et al. · Journal for ImmunoTherapy of Cancer · 2018 · 369 citations · Full text

Life Sciences, Immunology, Oncology +17

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

David Schaer, Sandaruwan Geeganage, Nelusha Amaladas et al. · Clinical Cancer Research · 2019 · 127 citations

Life Sciences, Immunology, Oncology +17

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Steven M. Bray, Jeeyun Lee, Seung Tae Kim et al. · Scientific Reports · 2019 · 82 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

William J. Gradishar, Denise A. Yardley, Rachel M. Layman et al. · Clinical Cancer Research · 2015 · 74 citations · Full text

Medicine, Oncology, Pharmacology +17